At molecular levels, we demonstrated that AT9283 treatments abrogated the MKK3 protein levels mainly through the targeting of the AURKA signalling, shedding lights on the relevance of MKK3/AURKA crosstalk in sustaining CRC malignancy. This evidence concerns the gene AURKA and colorectal carcinoma.